Skip to main content

KEYNOTE-361: Phase 3 Study of Pembrolizumab ± Chemotherapy Versus Chemotherapy Alone in Advanced Urothelial Cancer

Loriot
Yohann
Cancer Medicine & INSERM U981
Gustave Roussy, Université Paris-Saclay
Villejuif
France
Show all authors
Powles
Thomas
Barts Cancer Institute, Queen Mary University of London
London
United Kingdom
Gschwend
Juergen E.
Technical University of Munich
Munich
Germany
Bellmunt
Joaquim
Dana-Farber Cancer Institute
Boston
MA
United States
Geczi
Lajos
National Institute of Oncology
Budapest
Hungary
Vulsteke
Christof
Antwerp University, Center for Oncological Research
Antwerp
Belgium
Abdelsalam
Mahmoud
The Moncton Hospital
Moncton
NB
Canada
Gafanov
Rustem
Russian Scientific Center of Roentgenoradiology
Moscow
Russian Federation
Bae
Woo Kyun
Chonnam National University, Hwasun Hospital
Hwasun
Republic of Korea
Revesz
Janos
Borsod County Hospital
Miskolc
Hungary
Yamamoto
Yoshiaki
Yamaguchi University
Ube
Japan
Anido
Urbano
Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS)
Santiago de Compostela
Spain
Su
Wen-Pin
National Cheng Kung University (NCKU) Hospital
Tainan
Taiwan
Fleming
Mark
Virginia Oncology Associates, US Oncology Research
Norfolk
VA
United States
Markus
Maurice
Rocky Mountain Cancer Center
Colorado Springs
CO
United States
Feng
Dai
Merck & Co., Inc.
Kenilworth
NJ
United States
Poehlein
Christian
Merck & Co., Inc.
Kenilworth
NJ
United States
Alva
Ajjai
University of Michigan
Ann Arbor
MI
United States

Tabs

Speciality: 
Oncology (medical)
Keywords: 
pembrolizumab, PD-1, PD-L1